Readily available biomarkers predict poor survival in metastatic pancreatic cancer

  • M. Strijker (Creator)
  • Eran van Veldhuisen (Contributor)
  • Lydia G. van der Geest (Contributor)
  • Olivier R. Busch (Creator)
  • M. F. Bijlsma (Creator)
  • Nadia Haj Mohammad (Contributor)
  • Marjolein Y. Homs (Creator)
  • Jeanin E. van Hooft (Contributor)
  • Joanne Verheij (Creator)
  • J. M.P.G.M. de Vos-Geelen (Contributor)
  • Johanna W. Wilmink (Creator)
  • W. Ewout W. Steyerberg (Contributor)
  • Marc G. Besselink (Creator)
  • Hanneke van Laarhoven (Contributor)
  • Olivier R.C. Busch (Creator)
  • Johanna W. Wilmink (Creator)
  • Marc G. Besselink (Creator)
  • Hanneke W Van Laarhoven (Creator)

Dataset

Description

Identification of metastatic pancreatic cancer (mPC) patients with the worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients. Patients with s...
Date made available2021
PublisherTaylor & Francis

Cite this